CHEYENNE, Wyo., May 1, 2017 /PRNewswire/ -- The directors and management of NanoSave Technologies Inc. (OTC PINK: NNSV) announced today that it posted Q1 2017 Financial results, which reflect the company's recent acquisition of the Viritron VDX, Viritron VPN and Viritron Mini Lab Patents. The company continues to expand rapidly, corporate accountants have indicated that the first quarter numbers were clearly positive and may have exceeded initial expectations. "We feel very strongly that our numbers will be a pleasant surprise as we have now operated a full quarter after combining the operating accounts of NanoSave Technologies Inc. and N1 Technologies Inc. into a consolidated financial statement, with assets and revenues from both companies hitting all time highs. We are looking forward to opening new markets in the bio technology arenas and streamlining all aspects of our operations," says Company CEO Steve Lovern. The company envisages these new Bio Tech Patents and Technologies as an exceptional opportunity for our investors going forward. NanoSave Technologies designs, develops, manufactures and markets a wide range of nano-engineered products. Q1 Financials: http://www.otcmarkets.com/financialReportViewer?symbol=NNSV&id=170593
In Other News; work continues on the Borg Global Holdings transition. BGH of Duluth Georgia has agreed to purchase a controlling interest in NanoSave Technologies Inc. Borg Global Holdings a privately held International Conglomerate has agreed to purchase controlling interest in NanoSave Technologies Inc. (NNSV) in an all cash deal slated to close on or before June 1st 2017. The management of Borg Global Holdings will install new Directors to the company's board and appoint new executives to the management. Borg Global Holdings CEO R.T. Bailey stated. "We see this deal as a win-win for our investors and the shareholders of NanoSave Technologies, we are excited to be adding all the NanoSave Technologies' product and Patent portfolios to the Borg Global balance sheet including the highly anticipated Viritron VDX Biophage based Staph treatments, NanoSave Technologies is a Global leader in Nano Technology research and development and the integration of this company and its IP assets into the Borg Global family is a truly great addition." Visit: http://www.BorgGlobal.com
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "will" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nanosave-technologies-inc-posts-q1-2017-financial-results-300448464.html
SOURCE NanoSave Technologies Inc. NNSV